Oxcarbazepine for the Treatment of Chronic Peripheral Neuropathic Pain
NCT ID: NCT01302275
Last Updated: 2014-05-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
117 participants
INTERVENTIONAL
2011-02-28
2013-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pregabalin in CIPN
NCT02394951
Pregabalin vs Placebo in Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
NCT00143156
Induction of Drug Metabolism: In Vivo Comparison of Carbamazepine and Oxcarbazepine.
NCT00260247
Neuropathic Pain Syndrome Patient Study (MK-0000-072)
NCT00570310
A Study to Assess the Safety and Efficacy of 7 Days Treatment With a Novel Analgesic in Subjects With Peripheral Neuropathic Pain
NCT01485094
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
oxcarbazepine
Oxcarbazepine is gradually increased during 21 days from 300 mg x 1 daily to 2400 mg, and kept on that dose ( 2400 mg) for three weeks.
Oxcarbazepine
Oxcarbazepine capsules 300 mg is gradually increased from 300 mg/day to 2400 mg/day Placebo capsules increase from 1/day to 8/day
placebo
Oxcarbazepine
Oxcarbazepine capsules 300 mg is gradually increased from 300 mg/day to 2400 mg/day Placebo capsules increase from 1/day to 8/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oxcarbazepine
Oxcarbazepine capsules 300 mg is gradually increased from 300 mg/day to 2400 mg/day Placebo capsules increase from 1/day to 8/day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* definite or probable neuropathic pain
* diagnosis of polyneuropathy, postherpetic neuralgia or peripheral nerve inju
* pain duration \> 3 months
* pain rating at baseline \>= 4 point NRS
* Informed consent
Exclusion Criteria
* allergy to oxcarbazepine
* renal or hepatic impairment
* epilepsy
* depression and other serious psychiatric disorders
* serious medical condition
* previous treatment for neuropathic that cannot be stopped
* pregnancy
* patients expected not to be able to comply with study protocol
* treatment with anticonvulsants, antidepressant or opioids
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Danish Pain Research Center
OTHER
Innovative Medicines Initiative
OTHER
Søren H. Sindrup
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Søren H. Sindrup
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Søren H Sindrup, MD
Role: PRINCIPAL_INVESTIGATOR
Department of Neurology, Odense University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Danish Pain Research Center, Aarhus University Hospital
Aarhus, , Denmark
Department of Neurology, Odense University Hospital
Odense, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IMIOXC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.